Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 6/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARD | Q03181 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29053617 | 1.00 | HSP90AA1 (0.55) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL11899543 | 0.90 | HRH3 (0.68) | FAAHHRH3MEN1KMT2APPARG | |
| SCHEMBL8003011 | 0.86 | HSP90AA1 (0.53) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL314089 | 0.86 | HSP90AA1 (0.53) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL1703730 | 0.84 | ALDH1A1 (0.46) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL28318362 | 0.82 | HSP90AA1 (0.53) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL4627638 | 0.82 | HSP90AA1 (0.57) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL10456338 | 0.82 | HSP90AA1 (0.57) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL21151833 | 0.82 | HSP90AA1 (0.57) | HSP90AA1FAAHHRH3ALDH1A1MEN1 | |
| SCHEMBL456198 | 0.82 | HSP90AA1 (0.57) | HSP90AA1FAAHHRH3ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | disclosed |
| EP-0781138-B1 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | UNIV WAKE FOREST (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7294621-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294620-B2 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294619-B2 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1852121-A2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070099870-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY | 2007-05-03 | — | — | US | disclosed |
| US-7141557-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-28 | — | — | US | disclosed |
| US-7135584-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7129227-B1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080050-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040259845-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| US-5962437-A | HEPATITIS, HERPES AND AIDA VIRUS | WAKE FOREST UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | SGMS1, HDLBP, LIPC | HSP90AA1 2539/4885FAAH 297/4885HRH3 2670/4885 |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | LIPC, APOB, PNLIP | HSP90AA1 1163/4885FAAH 287/4885HRH3 2265/4885 |
| US-20040259845-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | HSP90AA1 1654/4885FAAH 210/4885HRH3 1200/4885 |
| US-20050080050-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | HSP90AA1 1654/4885FAAH 210/4885HRH3 1200/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | HSP90AA1 1061/4885FAAH 489/4885HRH3 3657/4885 |
| US-20070099870-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | HSP90AA1 1061/4885FAAH 489/4885HRH3 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.